The disclosure provides for highly soluble PEGylated compstatin peptides, which exhibit high binding affinities for complement and therapeutic efficacy in vitro. The disclosure further provides for pharmaceutical compositions comprising the PEGylated compstatin peptides, and methods of treatment thereof.

The present invention relates to elastomeric thermoplastic polymers (ETP) and especially technical polymers with high added value used in varied sectors, such as electronics, motor vehicles or sport. The present invention more particularly relates to copolymers containing polyether blocks and polyamide blocks, abbreviated as PEBA, which have good antistatic properties. Even more particularly, the invention relates to a copolymer containing at least one polyamide (PA) block, at least one polyethylene glycol (PEG) block and at least one block that is more hydrophobic than the PEG block. A subject of the invention is also a process for synthesizing such thermoplastic elastomers which have good antistatic properties and the use thereof in any type of thermoplastic polymer matrix in order to afford this matrix antistatic properties.

An encoding/decoding apparatus and method using a low-density parity-check code (LDPC code) is disclosed. Basic column group information, serving as a set of information regarding positions of rows with weight 1, is extracted from a reference column in each column group of a predetermined parity-check matrix. Column group information transforms the positions of rows with weight 1 into positions whose lengths are within a required parity length. A parity-check matrix is generated according to the generated column group information. Data is enclosed or decoded based on the generated parity-check matrix.

An encoding/decoding apparatus and method using a low-density parity-check code (LDPC code) is disclosed. Basic column group information, serving as a set of information regarding positions of rows with weight 1, is extracted from a reference column in each column group of a predetermined parity-check matrix. Column group information transforms the positions of rows with weight 1 into positions whose lengths are within a required parity length. A parity-check matrix is generated according to the generated column group information. Data is enclosed or decoded based on the generated parity-check matrix.

A process for preparing a copolymer polyol containing a reduced content of residual monomers and volatiles including the steps of: (a) providing at least one copolymer polyol containing a first initial content of residual monomers and volatiles; (b) providing at least one molecular sieve adsorbent; (c) contacting the at least one copolymer polyol with the at least one molecular sieve adsorbent for a period of time and at a temperature sufficient for the at least one molecular sieve adsorbent to adsorb at least a portion of the first initial content of residual monomers and volatiles present in the at least one copolymer polyol to reduce the first initial content of residual monomers and volatiles of the at least one copolymer polyol to form at least one copolymer polyol containing a second reduced content of residual monomers and volatiles; and (d) separating the at least one molecular sieve adsorbent containing a portion of the first initial content residual monomers and volatiles from the at least one copolymer polyol to form at least one copolymer polyol containing a second reduced content of residual monomers and volatiles.

A process for preparing a copolymer polyol containing a reduced content of residual monomers and volatiles including the steps of: (a) providing at least one copolymer polyol containing a first initial content of residual monomers and volatiles; (b) providing at least one molecular sieve adsorbent; (c) contacting the at least one copolymer polyol with the at least one molecular sieve adsorbent for a period of time and at a temperature sufficient for the at least one molecular sieve adsorbent to adsorb at least a portion of the first initial content of residual monomers and volatiles present in the at least one copolymer polyol to reduce the first initial content of residual monomers and volatiles of the at least one copolymer polyol to form at least one copolymer polyol containing a second reduced content of residual monomers and volatiles; and (d) separating the at least one molecular sieve adsorbent containing a portion of the first initial content residual monomers and volatiles from the at least one copolymer polyol to form at least one copolymer polyol containing a second reduced content of residual monomers and volatiles.

Embodiments of the invention provide derivatives of Amphotericin B having increased solubility and reduced toxicity relative to AMB, while retaining antifungal activity against multiple clinical fungal isolates. Derivatives of AMB are provided comprising a polymer group having an amine group, the polymer linked to mycosamine via a relatively stable linker such as an amide linker. The derivatives may be of the general formula [I]:

##STR00001##

wherein R is H, C.sub.1-4 alkyl or phenyl; R.sup.2 is (CH.sub.2).sub.m wherein m is between 0 and 4; R.sup.3 and R.sup.4 are each independently H or C.sub.1-4 alkyl, R.sup.5 is or OH, R.sup.6 is selected from a group consisting of: amide and alkyl, and R.sup.7 is a water-soluble polymer, and pharmaceutically acceptable salts, solvates, hydrates, diastereomers, and prodrugs of the compound of Formula [I].

Embodiments of the invention provide derivatives of Amphotericin B having increased solubility and reduced toxicity relative to AMB, while retaining antifungal activity against multiple clinical fungal isolates. Derivatives of AMB are provided comprising a polymer group having an amine group, the polymer linked to mycosamine via a relatively stable linker such as an amide linker. The derivatives may be of the general formula [I]:

##STR00001##

wherein R is H, C.sub.1-4 alkyl or phenyl; R.sup.2 is (CH.sub.2).sub.m wherein m is between 0 and 4; R.sup.3 and R.sup.4 are each independently H or C.sub.1-4 alkyl, R.sup.5 is or OH, R.sup.6 is selected from a group consisting of: amide and alkyl, and R.sup.7 is a water-soluble polymer, and pharmaceutically acceptable salts, solvates, hydrates, diastereomers, and prodrugs of the compound of Formula [I].

A polymer (A) having, at one terminal moiety thereof, a terminal structure having two or more carbon-carbon unsaturated bonds. A reactive-silicon-group-containing polymer (B) having, at one terminal moiety thereof, a terminal structure having two or more reactive silicon groups.

A polymer (A) having, at one terminal moiety thereof, a terminal structure having two or more carbon-carbon unsaturated bonds. A reactive-silicon-group-containing polymer (B) having, at one terminal moiety thereof, a terminal structure having two or more reactive silicon groups.